생식건강용 유전자 스크리닝 및 검사 시장 - 세계 및 지역 분석 : 제공, 검사 유형, 유전성 질환, 기술적 어프로치, 검체 유형, 최종사용자, 지역별 - 분석과 예측(2026-2036년)

This report can be delivered within 1 working day.

Introduction of the Genetic Screening and Testing for Reproductive Health Market

The global genetic screening and testing for reproductive health market, valued at $9,012.6 million in 2025, is projected to reach $24,709.7 million by 2036, registering a compound annual growth rate (CAGR) of 9.73% during 2026-2036.

The market encompasses products, software, and laboratory services used to identify chromosomal abnormalities, inherited conditions, and other genomic factors affecting fertility, embryo viability, pregnancy outcomes, or transmission risk. It supports preconception planning, indication-led infertility evaluation, assisted reproduction, embryo testing, prenatal screening, confirmatory prenatal diagnosis, and investigation of pregnancy loss. Principal test categories comprise carrier screening, infertility genetic testing, preimplantation genetic testing (PGT), non-invasive prenatal testing (NIPT), and other reproductive genetic tests.

Demand is expanding through routine use of cell-free DNA screening in prenatal care, increasing IVF and embryo-testing activity, ancestry-neutral carrier-screening strategies, improving sequencing capacity, and automated bioinformatics and interpretation. NIPT uses maternal blood and remains a screening test; positive or high-risk findings may require counseling and confirmatory diagnostic procedures. Market growth nevertheless depends on reimbursement, patient affordability, evidence of clinical utility, specialist counseling capacity, laboratory quality, regulatory requirements, and ethical acceptance.

Market Introduction

The global genetic screening and testing for reproductive health market includes commercially supplied products and laboratory services that identify genetic factors relevant to conception, fertility, embryo development, pregnancy, and inherited risk. In-scope tests comprise targeted and expanded carrier screening; indication-led infertility genetic testing; PGT for aneuploidy, structural rearrangements, monogenic disorders, and polygenic disorders; NIPT; invasive prenatal diagnosis; products-of-conception testing; and recurrent-pregnancy-loss genetic assessment.

The offering model combines products and services. Products include NGS-based, microarray-based, and other consumables and reagents; attributable sequencing, microarray, and cytogenetic instruments; and software and bioinformatics for quality control, variant analysis, workflow management, interpretation, and reporting. Services encompass sample processing, sequencing or cytogenetic analysis, bioinformatics, variant interpretation, clinical reporting, and testing support. Recurring laboratory-service and consumables expenditure therefore accompanies selective capital investment in analytical platforms.

Technology and specimen selection change across the reproductive pathway. Blood, saliva, and buccal swabs support carrier and infertility testing; embryonic cells obtained through biopsy support PGT; maternal blood containing cell-free DNA supports NIPT; and amniotic fluid or fetal and placental tissue supports diagnostic or pregnancy-loss investigations. Cytogenetics identifies chromosome-level abnormalities, microarray or SNP-array methods assess copy-number changes and selected variants, targeted NGS panels enable multiplexed analysis, and WES or WGS extends genomic breadth in selected applications.

Testing is delivered through local, outsourced, and hybrid models. High-volume hospitals, academic centers, and reference laboratories may maintain in-house platforms, validated pipelines, and bioinformatics teams. Fertility clinics, obstetric practices, and smaller providers commonly retain patient management and sample collection locally while outsourcing complex analysis and interpretation. This structure influences instrument purchasing, laboratory utilization, sample logistics, turnaround time, data exchange, and the share of value captured by centralized service providers.

Purchasing and referral decisions reflect clinical and analytical validation, reportable-result rates, test-menu breadth, turnaround time, automation, sample stability, bioinformatics performance, payer connectivity, regulatory readiness, counseling support, affordability, technical service, and supply reliability. For PGT, coordination among the fertility clinic, biopsy laboratory, courier, and genetics provider is especially important. For NIPT and carrier screening, electronic ordering, benefit verification, partner follow-up, and clear patient communication can materially affect completion and collection.

Broader analytical capability does not automatically create clinical value. Expanded NIPT content, universal PGT-A, PGT-P, and genome-scale reproductive testing remain sensitive to evidence, counseling requirements, consent, ethical restrictions, reimbursement, and interpretation uncertainty. Sustainable commercial growth is therefore expected to favor organizations that match validated technology with clinically appropriate indications, dependable operations, accessible pricing, secure data governance, and reporting that supports reproductive decision-making.

Industrial Impact

Genetic screening and testing is reshaping reproductive care by moving genomic information into preconception, fertility, embryo, prenatal, and pregnancy-loss pathways. Obstetric providers use NIPT to screen maternal blood for common fetal aneuploidies, while positive or high-risk results can lead to counseling and confirmatory prenatal diagnosis. Carrier screening informs inherited-risk discussions before or during pregnancy. Infertility genetic testing, products-of-conception analysis, and recurrent-pregnancy-loss assessment can identify selected chromosomal or molecular contributors where clinically indicated.

Within assisted reproduction, PGT-A assesses embryo aneuploidy, PGT-M addresses known monogenic risk, and PGT-SR evaluates structural rearrangements. These services connect fertility and IVF clinics with biopsy laboratories, couriers, genetic-testing laboratories, bioinformatics providers, and counselors. One treatment cycle can produce several biopsy samples, so case growth and sample growth may differ. Vitrolife AB and Yikon Genomics participate in embryo-testing workflows, while Natera, Inc., Myriad Genetics, Inc., Labcorp, Quest Diagnostics Incorporated, and Fulgent Genetics support reproductive testing through service networks and specialized menus.

The industrial model produces recurring revenue through laboratory services and per-test consumables around an installed base of sequencing, microarray, cytogenetic, and automation systems. Illumina, Inc., Thermo Fisher Scientific Inc., MGI Tech Co., Ltd., GeneMind Biosciences, Revvity, Inc., F. Hoffmann-La Roche Ltd., and Takara Bio Inc. supply enabling instruments, reagents, assays, or software for selected workflows. Centralized laboratories can achieve scale through high-throughput processing, standardized quality systems, payer contracting, interpretation expertise, and broad referral networks, whereas local testing can improve control over samples, data, and turnaround time.

Payers and patients influence whether technically available testing becomes completed and collectible revenue. Coverage criteria, prior authorization, deductibles, self-pay exposure, and IVF-related expenditure can reduce conversion or realized value. Geographic disparities also reflect laboratory accreditation, specialist and counseling capacity, cold-chain or specimen logistics, data-governance requirements, regulatory fragmentation, and ethical restrictions on embryo testing. Interpretation complexity and uncertain clinical utility can constrain expanded NIPT, universal PGT-A, PGT-P, and genome-wide approaches. Providers that combine clinical validity, reliable sample handling, transparent reporting, affordability, counseling support, and secure digital connectivity can reduce these barriers while supporting responsible adoption. The resulting impact extends from laboratory investment and workforce planning to payer policy, patient access, and the organization of cross-border testing networks.

Market Segmentation:

Segmentation 1: By Offering

• Product
  • Consumables and Reagents
  • Instruments
  • Software and Bioinformatics
• Services

Services to Lead the Global Genetic Screening and Testing for Reproductive Health Market (by Offering)

Services accounted for the largest market share in 2025 and are expected to grow faster during 2026-2036. Their leadership reflects the clinical complexity of reproductive testing, continued outsourcing by hospitals and fertility clinics, and the need for accredited processing, bioinformatics, interpretation, reporting, payer support, and sample logistics. Specialized laboratories also aggregate testing volume across referral networks, improving utilization of sequencing and cytogenetic infrastructure. Products remain essential to service delivery. Consumables and reagents form the principal recurring product category because each test requires collection, preparation, amplification, sequencing, array, control, or other assay inputs. Instruments and software support capacity, automation, quality control, variant analysis, workflow management, and clinical reporting.

Segmentation 2: By Test Type

• Carrier Screening
  • Expanded Carrier Screening
  • Targeted Carrier Screening
• Infertility Genetic Testing
• Preimplantation Genetic Testing (PGT)
  • Preimplantation Genetic Testing for Aneuploidy (PGT-A)
  • Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR)
  • Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)
  • Preimplantation Genetic Testing for Polygenic Disorders (PGT-P)
• Non-Invasive Prenatal Testing
• Others

Non-Invasive Prenatal Testing to Lead the Global Genetic Screening and Testing for Reproductive Health Market (by Test Type)

Non-invasive prenatal testing accounted for the largest test-type share in 2025 and is expected to grow fastest during 2026-2036. Its leadership is supported by maternal-blood collection, strong screening performance for common fetal aneuploidies, an annually renewing pregnancy population, and wider integration of cell-free DNA testing into prenatal care. NIPT remains a screening test; positive or high-risk findings require counseling and may warrant confirmatory diagnostic procedures. Carrier screening is expanding through broader, ancestry-neutral panels, while PGT grows with IVF and embryo-testing activity. Infertility genetic testing remains indication-led. Other tests include invasive prenatal diagnosis, products-of-conception testing, recurrent-pregnancy-loss assessment, and related reproductive genetic applications.

Segmentation 3: By Genetic Disorder

• Chromosomal Abnormalities
  • Aneuploidies
  • Structural Chromosomal Abnormalities
  • Copy Number Variations/Microdeletions and Microduplications
• Single-Gene/Monogenic Genetic Disorders
  • Autosomal Recessive Genetic Disorders
  • Autosomal Dominant Genetic Disorders
  • X-linked Genetic Disorders
• Others

Chromosomal Abnormalities to Lead the Global Genetic Screening and Testing for Reproductive Health Market (by Genetic Disorder)

Chromosomal abnormalities accounted for the largest genetic-disorder share in 2025, supported by NIPT for common fetal aneuploidies, PGT-A, cytogenetic analysis, microarrays, and confirmatory prenatal diagnosis. This segment includes aneuploidies, structural chromosomal abnormalities, and copy-number variations relevant to infertility, embryo viability, fetal development, and pregnancy outcomes. Single-gene and monogenic disorders are expected to grow fastest as expanded carrier screening, targeted NGS panels, PGT-M, WES, and WGS improve access to sequence-level assessment. Testing for autosomal recessive, autosomal dominant, and X-linked disorders is often guided by carrier status, family history, phenotype, or a known pathogenic variant. Growth remains dependent on clinical utility, interpretation quality, counseling, and reimbursement.

Segmentation 4: By Technology Approach

• Carrier Screening
  • Targeted NGS Panel-Based Carrier Screening
  • Whole-Exome Sequencing-Based Carrier Screening
  • Whole-Genome Sequencing-Based Carrier Screening
  • Microarray/SNP Genotyping-Based Carrier Screening
  • Others
• Infertility Genetic Testing
  • Cytogenetic Testing
  • Microarray/SNP Array-Based Testing
  • NGS Panel-Based Testing
  • Others
• Preimplantation Genetic Testing (PGT)
  • Whole-Genome Sequencing-Based PGT
  • Targeted NGS-Based PGT
  • Others
• Non-Invasive Prenatal Testing
  • Whole-Genome Sequencing/Massively Parallel Shotgun Sequencing-Based NIPT
  • Targeted Approach-Based NIPT
  • Others
• Others
  • NGS-Based Testing
  • Microarray-Based Testing
  • Other Approaches

Targeted NGS Panel-Based Carrier Screening to Lead the Global Genetic Screening and Testing for Reproductive Health Market (Technology Approach, by Carrier Screening)

At the second level, targeted NGS panel-based carrier screening leads the carrier-screening technology mix in 2025 because it supports multiplexed analysis of clinically selected genes with established workflows and manageable interpretation. Whole-genome sequencing-based carrier screening is expected to grow fastest as coverage improves and laboratories evaluate broader, more uniform analysis; WES is also gaining relevance, while microarray/SNP genotyping and other methods remain useful for established variants and cost-sensitive programs. In infertility genetic testing, NGS panels support simultaneous gene assessment, whereas cytogenetic and microarray/SNP-array methods address chromosome-level and copy-number abnormalities. Targeted NGS leads current PGT workflows, with WGS-based PGT expanding faster. Within NIPT, whole-genome or massively parallel shotgun sequencing is the leading approach; targeted SNP, microarray, rolling-circle amplification, and other approaches support focused or alternative workflows. Other reproductive tests use NGS, microarrays, and additional molecular methods according to clinical indication, sample, validation, cost, and laboratory capability. Across branches, broader coverage raises bioinformatics, counseling, evidence, quality-control, and data-governance requirements, so analytical breadth must be matched with clinically interpretable reporting and regulatory acceptance.

Segmentation 5: By Sample Type

• Blood
• Saliva
• Buccal Swab
• Embryonic Cells
• Amniotic Fluid
• Fetal and Placental Tissue
• Others

Blood to Lead the Global Genetic Screening and Testing for Reproductive Health Market (by Sample Type)

Blood accounted for the largest sample-type share in 2025 because maternal blood underpins NIPT and blood is also widely used in carrier screening, infertility genetic testing, and selected confirmatory workflows. Established collection procedures, broad platform compatibility, and availability support continued leadership. Saliva is expected to grow fastest as remote and at-home collection, digital ordering, and reduced dependence on phlebotomy expand access to carrier and reproductive-risk testing. Buccal swabs provide another simple DNA source. Embryonic cells remain specific to PGT following biopsy, while amniotic fluid and fetal or placental tissue support confirmatory prenatal diagnosis, products-of-conception testing, and pregnancy-loss investigations. Method selection depends on indication, safety, stability, DNA quality, logistics, and validated laboratory requirements.

Segmentation 6: By End User

• Hospitals
• Fertility and IVF Clinics
• Diagnostic, Reference, and Genetic Testing Laboratories
• Others

Diagnostic, Reference, and Genetic Testing Laboratories to Lead the Global Genetic Screening and Testing for Reproductive Health Market (by End User)

Diagnostic, reference, and genetic testing laboratories accounted for the largest end-user share in 2025 and are expected to grow fastest during 2026-2036. Their leadership reflects specialized sequencing and cytogenetic platforms, validated assays, accreditation, bioinformatics, qualified interpretation teams, quality systems, and high-throughput processing. Outsourcing from hospitals, obstetric practices, and fertility clinics further concentrates complex testing in centralized laboratories, which can also manage payer requirements, sample logistics, reporting, and provider connectivity. Hospitals coordinate prenatal screening, diagnosis, counseling, and follow-up care, while fertility and IVF clinics generate demand for carrier screening, infertility genetic testing, and PGT. Other users include academic, government, research, and telehealth-enabled organizations.

Segmentation 7: By Region

• North America
  • U.S.
  • Canada
• Europe, Middle East and Africa
  • Western Europe
  • Commonwealth of Independent States (CIS)
  • Nordics and South-Eastern/Central Eastern Europe (NSSE)
  • Middle East
  • Africa
  • Rest-of-Europe
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Taiwan
  • Thailand
  • Vietnam
  • Malaysia
  • Rest-of-Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Costa Rica
  • Ecuador
  • Panama
  • Puerto Rico
  • Dominican Republic
  • Rest-of-Latin America

North America to Lead the Global Genetic Screening and Testing for Reproductive Health Market (by Region)

North America accounted for the largest regional share in 2025, supported by mature obstetric and fertility-care pathways, extensive sequencing infrastructure, established reimbursement mechanisms, and a dense base of reference laboratories, fertility centers, reproductive genetics companies, and specialized professionals. The U.S. anchors the region through broad access to carrier screening, NIPT, PGT, and indication-led infertility genetic testing. Clinical guidance, ART reporting, payer connectivity, physician awareness, and developed laboratory networks reinforce recurring testing, although coverage and patient cost exposure remain uneven.

Asia-Pacific is expected to grow fastest during 2026-2036. Large reproductive-age and birth populations, expanding IVF utilization, rising awareness of inherited risk, and investment in domestic sequencing platforms, genomic laboratories, and reproductive-health infrastructure support growth. China, India, Japan, South Korea, and Australia are increasing prenatal screening and embryo-testing capacity. Domestic platforms and regional partnerships can improve affordability and service reach, subject to local validation and regulation.

Europe, Middle East and Africa remains significant through public prenatal programs, fertility networks, national genomics initiatives, and specialized laboratories, but reimbursement, ethical frameworks, accreditation, and capabilities differ across subregions. Latin America is expanding through private laboratory investment, fertility-clinic development, and increasing prenatal and carrier-screening use. Across both regions, affordability, specialist availability, sample logistics, data governance, regulation, and public-versus-private access will shape adoption.

Recent Developments in the Genetic Screening and Testing for Reproductive Health Market

• In July 2026, Myriad Genetics, Inc. launched the FirstGene Multiple Prenatal Screen, extending its reproductive-health portfolio toward simplified prenatal screening workflows. The launch supports integration of multiple screening needs within coordinated sample, interpretation, and reporting pathways for clinicians and patients, while broadening the company's engagement across prenatal care.
• In June 2026, F. Hoffmann-La Roche Ltd. launched the AXELIOS 1 sequencing platform. The platform creates a longer-term opportunity to support carrier screening, PGT, prenatal testing, and related reproductive genomics, subject to application-specific clinical validation, workflow development, laboratory adoption, and regulatory approval.
• In May 2026, Natera, Inc. announced an enhanced Panorama workflow with a reduced no-call rate. The update is intended to improve the proportion of maternal samples producing reportable NIPT results and strengthen laboratory efficiency, physician experience, and patient completion.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Routine Integration of NIPT into Prenatal Care Driving Recurring Testing Volume: Routine integration of NIPT into prenatal care creates recurring demand linked to successive pregnancy cohorts. Each completed maternal-blood screen supports laboratory services, collection materials, logistics, sequencing or alternative detection consumables, bioinformatics, quality control, interpretation, and reporting. Wider eligibility for common-aneuploidy screening can increase physician ordering and patient access, particularly where guidance and organized programs support implementation. However, adoption varies with reimbursement, benefit design, laboratory capacity, and counseling pathways. Testing-volume growth may not translate directly into equal revenue growth because public procurement, payer contracting, competition, lower failure rates, and declining analytical costs can change average realized value per completed test.

Expanding ART Throughput Supporting PGT and Embryo-Biopsy Utilization: Expanding assisted reproductive technology throughput enlarges the clinical base for PGT-A, PGT-M, PGT-SR, embryo-biopsy coordination, and related laboratory analysis. Growth in IVF cycles, blastocyst biopsy, cryopreservation, and frozen-embryo transfer can increase case volume and the number of samples submitted to genetics laboratories. Commercial demand reaches fertility clinics, biopsy laboratories, couriers, sequencing and amplification consumables, bioinformatics, counseling, and reporting. Adoption nevertheless depends on maternal age, indication, embryo yield, evidence, regulation, reimbursement, and patient preference. Market revenue may not rise one-for-one with IVF cycles because some cycles produce no testable embryos, while bundled pricing, multiple biopsies, and laboratory efficiency alter value per case.

Market Challenges

Coverage Gaps and Patient Cost Exposure Limiting Reproductive Genetic-Test Access: Coverage for reproductive genetic testing remains inconsistent across payers, indications, test categories, and countries. Medical-necessity criteria, prior authorization, limited networks, deductibles, coinsurance, denials, and uncertain bills can prevent orders from progressing to completed testing. Public programs may fund common-aneuploidy NIPT or selected carrier conditions while broader panels remain privately insured or self-paid. Cost exposure is influential when PGT is added to an expensive IVF pathway. Laboratories face lower completion, delayed collection, administrative expense, contractual adjustments, and difficult patient balances. Transparent estimates, benefit verification, appeals support, evidence generation, payer contracting, and disciplined test menus can improve access but cannot eliminate geographic and plan-level variation.

Market Opportunities

Expansion of Ancestry-Neutral Carrier Screening into Preconception Care: Ancestry-neutral carrier screening could expand preconception testing beyond individuals identified through family history or traditional ethnic-risk categories. Professional guidance supports offering screening to people who are pregnant or planning pregnancy, creating opportunities in primary care, obstetrics, fertility services, employer benefits, and community channels. Digital education and ordering, saliva collection, coordinated partner testing, couple-level reporting, and tele-genetic counseling can improve completion before pregnancy-related time pressure develops. Adoption is not assured: payer coverage, clinician awareness, panel discipline, variant interpretation, counseling capacity, equitable analytical performance, and referral pathways remain essential. Growth should depend more on reaching unscreened individuals and completing partner pathways than on continually expanding gene counts.

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Segmentation and testing-volume analysis help organizations prioritize assays, instruments, consumables, software, sample compatibility, automation, interpretation, and unmet workflows across carrier screening, infertility testing, PGT, NIPT, prenatal diagnosis, and pregnancy-loss assessment. The findings also support platform configuration and evidence planning.

Growth/Marketing Strategy: The report helps organizations compare test types, end users, referral channels, payer approaches, partnerships, geographic markets, and local, outsourced, or hybrid testing models. Country-level value and volume forecasts support channel planning, laboratory expansion, benefit strategies, commercial resource allocation, and prioritization of underpenetrated patient pathways.

Competitive Strategy: Company-share analysis, product benchmarking, portfolio breadth, strategic developments, clinical evidence, laboratory reach, installed-base access, regulatory capability, payer connectivity, and service quality help market participants evaluate positioning, partnership opportunities, competitive gaps, acquisition targets, regional strengths, and capabilities needed for sustainable differentiation.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Years from 2024 to 2036 have been considered for market estimation; 2025 is the base year, and 2026-2036 is the forecast period.
• Ecosystem inputs cover assay and instrument companies, sequencing-platform providers, software and bioinformatics suppliers, distributors, reproductive genetic-testing laboratories, diagnostic and reference laboratories, hospitals, fertility and IVF clinics, payers, and relevant healthcare professionals.
• Public-company financial information is drawn from annual reports and investor materials; private-company estimates use disclosed funding, partnerships, operating indicators, and validated research inputs and are not represented as reported revenue.
• Product and service mapping, testing volume, representative pricing, company revenue, segment splits, and regional validation are triangulated to estimate and forecast the market.

Primary Research

Primary research covers product and platform suppliers, service laboratories, hospitals, fertility and IVF clinics, distributors, genetic counselors, maternal-fetal medicine and reproductive specialists, payers, and laboratory or commercial decision-makers. Relevant roles include executives, product and business-development leaders, laboratory directors, clinical geneticists, bioinformatics specialists, quality and regulatory professionals, procurement heads, and operations managers. Interviews and stakeholder consultation across major regions and testing models support validation of qualitative and quantitative findings.

The key data points intended from primary sources include:

• validation and triangulation of market numbers and graphs
• validation of report segmentation and qualitative findings
• testing volume and PGT-A biopsy-sample volume
• average selling prices and service pricing
• competitive landscape, business models, and local versus outsourced testing
• regional percentage splits

Secondary Research

Open Sources

• Recognized publications, professional-society guidance, and peer-reviewed literature
• Government and regulator publications, national registries, and screening programs
• Annual reports, regulatory filings, and investor presentations of leading market participants
• Company websites, product documentation, official press releases, and reputable news sources
• Paid databases

The key data points taken from secondary sources include:

• market segmentation and percentage-share inputs
• market values and testing volumes
• company, portfolio, and strategic-development trends
• technology, workflow, regulatory, reimbursement, and access developments
• quantitative inputs used for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The global genetic screening and testing for reproductive health market combines specialized testing-service providers, diversified diagnostic laboratory networks, sequencing-platform companies, fertility-focused laboratories, assay manufacturers, and regional genetic-testing specialists. Service providers compete through clinical validation, test-menu breadth, analytical accuracy, turnaround time, payer access, physician and fertility-clinic relationships, genetic-counseling support, sample logistics, and reporting quality. These capabilities determine whether an order progresses efficiently from collection to an interpretable result and whether the provider can support complex reproductive decisions.

Competition on the product and platform side centers on sequencing performance, instrument placement, reagent economics, workflow automation, assay compatibility, bioinformatics integration, regulatory approvals, and technical support. Thermo Fisher Scientific Inc., Illumina, Inc., Revvity, Inc., GeneMind Biosciences, F. Hoffmann-La Roche Ltd., Takara Bio Inc., and MGI Tech Co., Ltd. participate through instruments, assays, reagents, or software. Natera, Inc., Myriad Genetics, Inc., Labcorp, Quest Diagnostics Incorporated, Vitrolife AB, Fulgent Genetics, and Yikon Genomics compete through testing services or reproductive-health specialization.

Market participants are strengthening their positions through product and service launches, regulatory approvals, partnerships, acquisitions, laboratory expansion, automation, and integrated digital reporting. Competitive advantage increasingly depends on combining reliable workflows with affordability, payer connectivity, clinical evidence, counseling pathways, and reach. Regional providers remain influential because regulation, language, data-localization requirements, reimbursement, referral relationships, and sample logistics vary materially across countries. The market is therefore expected to retain a diverse structure even as consolidation and platform-service partnerships continue.

Some prominent names established in this market are:

• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Revvity, Inc.
• GeneMind Biosciences
• F. Hoffmann-La Roche Ltd.
• Yikon Genomics
• Takara Bio Inc.
• MGI Tech Co., Ltd.
• Natera, Inc.
• Myriad Genetics, Inc.
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated
• Vitrolife AB
• Fulgent Genetics

Table of Contents

Executive Summary

Scope and Definition

1 Global Genetic Screening and Testing for Reproductive Health Market: Industry Outlook

• 1.1 Market Overview
• 1.2 Market Ecosystem
  • 1.2.1 Reproductive Genetic Screening and Testing Workflow
    • 1.2.1.1 Patient/Couple Assessment and Genetic Counseling
    • 1.2.1.2 Selection of Reproductive Genetic Test
    • 1.2.1.3 Sample Collection and Preparation
    • 1.2.1.4 Laboratory Processing and Genetic Analysis
    • 1.2.1.5 Bioinformatics, Variant Analysis, and Interpretation
    • 1.2.1.6 Reporting and Post-Test Genetic Counseling
    • 1.2.1.7 Reproductive and Clinical Decision-Making
  • 1.2.2 Testing Methodology Landscape
    • 1.2.2.1 Biochemical
    • 1.2.2.2 Chromosomal
    • 1.2.2.3 Molecular
  • 1.2.3 Testing Adoption Landscape
    • 1.2.3.1 By Test Type
    • 1.2.3.2 By Testing Model (Local vs. Outsourced)
  • 1.2.4 Pricing, Reimbursement, and Access Landscape
  • 1.2.5 Future Outlook
• 1.3 Market Trends
  • 1.3.1 Trends: Current and Future Impact Assessment
    • 1.3.1.1 Impact Analysis
      • 1.3.1.1.1 Shift from Targeted Panels toward Genome-Scale Reproductive Genetic Testing
      • 1.3.1.1.2 Consolidation of Sequential Tests into Integrated Reproductive Genetic Assays
      • 1.3.1.1.3 Transition from Centralized Send-Out Testing toward Local In-Lab Workflows
• 1.4 Regulatory Landscape
  • 1.4.1 North America
    • 1.4.1.1 U.S.
    • 1.4.1.2 Canada
  • 1.4.2 Europe, the Middle East and Africa
    • 1.4.2.1 Western Europe
    • 1.4.2.2 Commonwealth of Independent States
      • 1.4.2.2.1 Russia
      • 1.4.2.2.2 Kazakhstan
      • 1.4.2.2.3 Belarus
    • 1.4.2.3 Nordics and South-Eastern/Central Eastern Europe
    • 1.4.2.4 Middle East
    • 1.4.2.5 Africa
  • 1.4.3 Asia-Pacific
    • 1.4.3.1 China
    • 1.4.3.2 Japan
    • 1.4.3.3 India
    • 1.4.3.4 South Korea
    • 1.4.3.5 Taiwan
    • 1.4.3.6 Thailand
    • 1.4.3.7 Vietnam
    • 1.4.3.8 Malaysia
    • 1.4.3.9 Australia
  • 1.4.4 Latin America
    • 1.4.4.1 Brazil
    • 1.4.4.2 Mexico
    • 1.4.4.3 Argentina
    • 1.4.4.4 Chile
    • 1.4.4.5 Colombia
    • 1.4.4.6 Costa Rica
• 1.5 Market Dynamics
  • 1.5.1 Market Drivers
    • 1.5.1.1 Routine Integration of NIPT into Prenatal Care Driving Recurring Testing Volume
    • 1.5.1.2 Expanding ART Throughput Supporting PGT and Embryo-Biopsy Utilization
    • 1.5.1.3 Integration of Carrier Screening into Prenatal and Fertility-Care Workflows
  • 1.5.2 Market Restraints
    • 1.5.2.1 Coverage Gaps and Patient Cost Exposure Limiting Reproductive Genetic-Test Access
    • 1.5.2.2 Clinical-Utility Uncertainty Restricting Routine PGT-A and Expanded NIPT Adoption
    • 1.5.2.3 Regulatory and Ethical Restrictions Limiting PGT Availability and Commercialization
  • 1.5.3 Market Opportunities
    • 1.5.3.1 Expansion of Ancestry-Neutral Carrier Screening into Preconception Care
    • 1.5.3.2 Genomic Testing for Unexplained Infertility and Pregnancy Loss
    • 1.5.3.3 Clinical Expansion of Monogenic and Genome-Wide Prenatal Screening

2 Global Genetic Screening and Testing for Reproductive Health Market (by Offering), $Million, 2024-2036

• 2.1 Product
  • 2.1.1 Market Sizing and Forecast
  • 2.1.2 Consumables and Reagents
    • 2.1.2.1 Market Sizing and Forecast
    • 2.1.2.2 NGS-Based Consumables and Reagents
    • 2.1.2.3 Market Sizing and Forecast
    • 2.1.2.4 Microarray-Based Consumables and Reagents
    • 2.1.2.5 Market Sizing and Forecast
    • 2.1.2.6 Other Consumables and Reagents
    • 2.1.2.7 Market Sizing and Forecast
  • 2.1.3 Instruments
    • 2.1.3.1 Market Sizing and Forecast
  • 2.1.4 Software and Bioinformatics
    • 2.1.4.1 Market Sizing and Forecast
• 2.2 Services
  • 2.2.1 Market Sizing and Forecast

3 Global Genetic Screening and Testing for Reproductive Health Market (by Test Type), $Million, 2024-2036

• 3.1 Carrier Screening
  • 3.1.1 Market Sizing and Forecast
  • 3.1.2 Expanded Carrier Screening
    • 3.1.2.1 Market Sizing and Forecast
  • 3.1.3 Targeted Carrier Screening
    • 3.1.3.1 Market Sizing and Forecast
• 3.2 Infertility Genetic Testing
  • 3.2.1 Market Sizing and Forecast
• 3.3 Preimplantation Genetic Testing (PGT)
  • 3.3.1 Market Sizing and Forecast
  • 3.3.2 Preimplantation Genetic Testing for Aneuploidy (PGT-A)
    • 3.3.2.1 Market Sizing and Forecast
  • 3.3.3 Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR)
    • 3.3.3.1 Market Sizing and Forecast
  • 3.3.4 Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)
    • 3.3.4.1 Market Sizing and Forecast
  • 3.3.5 Preimplantation Genetic Testing for Polygenic Disorders (PGT-P)
    • 3.3.5.1 Market Sizing and Forecast
• 3.4 Non-Invasive Prenatal Testing
  • 3.4.1 Market Sizing and Forecast
• 3.5 Others
  • 3.5.1 Market Sizing and Forecast

4 Global Genetic Screening and Testing for Reproductive Health Market (by Genetic Disorder), $Million, 2024-2036

• 4.1 Chromosomal Abnormalities
  • 4.1.1 Market Sizing and Forecast
  • 4.1.2 Aneuploidies
    • 4.1.2.1 Market Sizing and Forecast
  • 4.1.3 Structural Chromosomal Abnormalities
    • 4.1.3.1 Market Sizing and Forecast
  • 4.1.4 Copy Number Variations/Microdeletions and Microduplications
    • 4.1.4.1 Market Sizing and Forecast
• 4.2 Single-Gene/Monogenic Genetic Disorders
  • 4.2.1 Market Sizing and Forecast
  • 4.2.2 Autosomal Recessive Genetic Disorders
    • 4.2.2.1 Market Sizing and Forecast
  • 4.2.3 Autosomal Dominant Genetic Disorders
    • 4.2.3.1 Market Sizing and Forecast
  • 4.2.4 X-Linked Genetic Disorders
    • 4.2.4.1 Market Sizing and Forecast
• 4.3 Others
  • 4.3.1 Market Sizing and Forecast

5 Global Genetic Screening and Testing for Reproductive Health Market (by Technology Approach), $Million, 2024-2036

• 5.1 Carrier Screening
  • 5.1.1 Market Sizing and Forecast
  • 5.1.2 Targeted NGS Panel-Based Carrier Screening
    • 5.1.2.1 Market Sizing and Forecast
  • 5.1.3 Whole-Exome Sequencing-Based Carrier Screening
    • 5.1.3.1 Market Sizing and Forecast
  • 5.1.4 Whole-Genome Sequencing-Based Carrier Screening
    • 5.1.4.1 Market Sizing and Forecast
  • 5.1.5 Microarray/SNP Genotyping-Based Carrier Screening
    • 5.1.5.1 Market Sizing and Forecast
  • 5.1.6 Others
    • 5.1.6.1 Market Sizing and Forecast
• 5.2 Infertility Genetic Testing
  • 5.2.1 Market Sizing and Forecast
  • 5.2.2 Cytogenetic Testing
    • 5.2.2.1 Market Sizing and Forecast
  • 5.2.3 Microarray/SNP Array-Based Testing
    • 5.2.3.1 Market Sizing and Forecast
  • 5.2.4 NGS Panel-Based Testing
    • 5.2.4.1 Market Sizing and Forecast
  • 5.2.5 Others
    • 5.2.5.1 Market Sizing and Forecast
• 5.3 Preimplantation Genetic Testing (PGT)
  • 5.3.1 Market Sizing and Forecast
  • 5.3.2 Whole-Genome Sequencing-Based PGT
    • 5.3.2.1 Market Sizing and Forecast
  • 5.3.3 Targeted NGS-Based PGT
    • 5.3.3.1 Market Sizing and Forecast
  • 5.3.4 Others
    • 5.3.4.1 Market Sizing and Forecast
• 5.4 Non-Invasive Prenatal Testing
  • 5.4.1 Market Sizing and Forecast
  • 5.4.2 Whole-Genome Sequencing/Massively Parallel Shotgun Sequencing-Based NIPT
    • 5.4.2.1 Market Sizing and Forecast
  • 5.4.3 Targeted Approach-Based NIPT
    • 5.4.3.1 Market Sizing and Forecast
    • 5.4.3.2 SNP Analysis
    • 5.4.3.3 Market Sizing and Forecast
    • 5.4.3.4 Microarray Analysis
    • 5.4.3.5 Market Sizing and Forecast
    • 5.4.3.6 Rolling Circle Amplification-Based NIPT
    • 5.4.3.7 Market Sizing and Forecast
  • 5.4.4 Others
    • 5.4.4.1 Market Sizing and Forecast
• 5.5 Others
  • 5.5.1 Market Sizing and Forecast
  • 5.5.2 NGS-Based Testing
    • 5.5.2.1 Market Sizing and Forecast
  • 5.5.3 Microarray-Based Testing
    • 5.5.3.1 Market Sizing and Forecast
  • 5.5.4 Other Approaches
    • 5.5.4.1 Market Sizing and Forecast

6 Global Genetic Screening and Testing for Reproductive Health Market (by Sample Type), $Million, 2024-2036

• 6.1 Blood
  • 6.1.1 Market Sizing and Forecast
• 6.2 Saliva
  • 6.2.1 Market Sizing and Forecast
• 6.3 Buccal Swab
  • 6.3.1 Market Sizing and Forecast
• 6.4 Embryonic Cells
  • 6.4.1 Market Sizing and Forecast
• 6.5 Amniotic Fluid
  • 6.5.1 Market Sizing and Forecast
• 6.6 Fetal and Placental Tissue
  • 6.6.1 Market Sizing and Forecast
• 6.7 Others
  • 6.7.1 Market Sizing and Forecast

7 Global Genetic Screening and Testing for Reproductive Health Market (by End User), $Million, 2024-2036

• 7.1 Hospitals
  • 7.1.1 Market Sizing and Forecast
• 7.2 Fertility and IVF Clinics
  • 7.2.1 Market Sizing and Forecast
• 7.3 Diagnostic, Reference, and Genetic Testing Laboratories
  • 7.3.1 Market Sizing and Forecast
• 7.4 Others
  • 7.4.1 Market Sizing and Forecast

8 Global Genetic Screening and Testing for Reproductive Health Market (by Region), $Million, 2024-2036

• 8.1 Regional Summary
• 8.2 North America
  • 8.2.1 Regional Overview
  • 8.2.2 Driving Factors for Market Growth
  • 8.2.3 Factors Challenging the Market
  • 8.2.4 Key Companies Operating in the Region
  • 8.2.5 Analyst View
  • 8.2.6 Market Sizing and Forecast
    • 8.2.6.1 North America Genetic Screening and Testing for Reproductive Health Market, by Country
    • 8.2.6.2 North America Genetic Screening and Testing for Reproductive Health Market, by Testing Volume
    • 8.2.6.3 North America Genetic Screening and Testing for Reproductive Health Market, by Testing Volume, by Preimplantation Genetic Testing (PGT)
    • 8.2.6.4 North America Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by PGT-A Biopsy Samples Tested
    • 8.2.6.5 North America Genetic Screening and Testing for Reproductive Health Market, by Offering
    • 8.2.6.6 North America Genetic Screening and Testing for Reproductive Health Market, by Products
    • 8.2.6.7 North America Genetic Screening and Testing for Reproductive Health Market, by Test Type
    • 8.2.6.8 North America Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Carrier Screening)
    • 8.2.6.9 North America Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Preimplantation Genetic Testing (PGT))
    • 8.2.6.10 North America Genetic Screening and Testing for Reproductive Health Market, By Technology Approach
    • 8.2.6.11 North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Carrier Screening
    • 8.2.6.12 North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Infertility Genetic Testing
    • 8.2.6.13 North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Preimplantation Genetic Testing (PGT)
    • 8.2.6.14 North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Non-Invasive Prenatal Testing
    • 8.2.6.15 North America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Others
      • 8.2.6.15.1 U.S.
        • 8.2.6.15.1.1 Country Overview
        • 8.2.6.15.1.2 Driving Factors for Market Growth
        • 8.2.6.15.1.3 Factors Challenging the Market
        • 8.2.6.15.1.4 Key Companies Operating in the Country
        • 8.2.6.15.1.5 Analyst View
        • 8.2.6.15.1.6 Market Sizing and Forecast
      • 8.2.6.15.2 Canada
        • 8.2.6.15.2.1 Country Overview
        • 8.2.6.15.2.2 Driving Factors for Market Growth
        • 8.2.6.15.2.3 Factors Challenging the Market
        • 8.2.6.15.2.4 Key Companies Operating in the Country
        • 8.2.6.15.2.5 Analyst View
        • 8.2.6.15.2.6 Market Sizing and Forecast
• 8.3 Europe, Middle East and Africa
  • 8.3.1 Regional Overview
  • 8.3.2 Driving Factors for Market Growth
  • 8.3.3 Factors Challenging the Market
  • 8.3.4 Key Companies Operating in the Region
  • 8.3.5 Analyst View
  • 8.3.6 Market Sizing and Forecast
    • 8.3.6.1 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, by Country
    • 8.3.6.2 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, by Testing Volume
    • 8.3.6.3 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, by Testing Volume, by Preimplantation Genetic Testing (PGT)
    • 8.3.6.4 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by PGT-A Biopsy Samples Tested
    • 8.3.6.5 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, by Offering
    • 8.3.6.6 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, by Products
    • 8.3.6.7 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, by Test Type
    • 8.3.6.8 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Carrier Screening)
    • 8.3.6.9 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Preimplantation Genetic Testing (PGT))
    • 8.3.6.10 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, By Technology Approach
    • 8.3.6.11 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Carrier Screening
    • 8.3.6.12 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Infertility Genetic Testing
    • 8.3.6.13 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Preimplantation Genetic Testing (PGT)
    • 8.3.6.14 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Non-Invasive Prenatal Testing
    • 8.3.6.15 Europe, Middle East and Africa Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Others
      • 8.3.6.15.1 Western Europe
        • 8.3.6.15.1.1 Country Overview
        • 8.3.6.15.1.2 Driving Factors for Market Growth
        • 8.3.6.15.1.3 Factors Challenging the Market
        • 8.3.6.15.1.4 Key Companies Operating in the Sub-Region
        • 8.3.6.15.1.5 Analyst View
        • 8.3.6.15.1.6 Market Sizing and Forecast
      • 8.3.6.15.2 Commonwealth of Independent States (CIS)
        • 8.3.6.15.2.1 Country Overview
        • 8.3.6.15.2.2 Driving Factors for Market Growth
        • 8.3.6.15.2.3 Factors Challenging the Market
        • 8.3.6.15.2.4 Key Companies Operating in the Sub-Region
        • 8.3.6.15.2.5 Analyst View
        • 8.3.6.15.2.6 Market Sizing and Forecast
      • 8.3.6.15.3 Nordics and South-Eastern/Central Eastern Europe (NSSE)
        • 8.3.6.15.3.1 Country Overview
        • 8.3.6.15.3.2 Driving Factors for Market Growth
        • 8.3.6.15.3.3 Factors Challenging the Market
        • 8.3.6.15.3.4 Analyst View
        • 8.3.6.15.3.5 Market Sizing and Forecast
      • 8.3.6.15.4 Middle East
        • 8.3.6.15.4.1 Country Overview
        • 8.3.6.15.4.2 Driving Factors for Market Growth
        • 8.3.6.15.4.3 Factors Challenging the Market
        • 8.3.6.15.4.4 Key Companies Operating in the Sub-Region
        • 8.3.6.15.4.5 Analyst View
        • 8.3.6.15.4.6 Market Sizing and Forecast
      • 8.3.6.15.5 Africa
        • 8.3.6.15.5.1 Country Overview
        • 8.3.6.15.5.2 Driving Factors for Market Growth
        • 8.3.6.15.5.3 Factors Challenging the Market
        • 8.3.6.15.5.4 Key Companies Operating in the Sub-Region
        • 8.3.6.15.5.5 Analyst View
        • 8.3.6.15.5.6 Market Sizing and Forecast
• 8.4 Asia-Pacific
  • 8.4.1 Regional Overview
  • 8.4.2 Driving Factors for Market Growth
  • 8.4.3 Factors Challenging the Market
  • 8.4.4 Key Companies Operating in the Region
  • 8.4.5 Analyst View
  • 8.4.6 Market Sizing and Forecast
    • 8.4.6.1 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, by Country
    • 8.4.6.2 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, by Testing Volume
    • 8.4.6.3 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, by Testing Volume, by Preimplantation Genetic Testing (PGT)
    • 8.4.6.4 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by PGT-A Biopsy Samples Tested
    • 8.4.6.5 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, by Offering
    • 8.4.6.6 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, by Products
    • 8.4.6.7 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, by Test Type
    • 8.4.6.8 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Carrier Screening)
    • 8.4.6.9 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Preimplantation Genetic Testing (PGT))
    • 8.4.6.10 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, By Technology Approach
    • 8.4.6.11 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Carrier Screening
    • 8.4.6.12 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Infertility Genetic Testing
    • 8.4.6.13 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Preimplantation Genetic Testing (PGT)
    • 8.4.6.14 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Non-Invasive Prenatal Testing
    • 8.4.6.15 Asia-Pacific Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Others
      • 8.4.6.15.1 China
        • 8.4.6.15.1.1 Country Overview
        • 8.4.6.15.1.2 Driving Factors for Market Growth
        • 8.4.6.15.1.3 Factors Challenging the Market
        • 8.4.6.15.1.4 Key Companies Operating in the Country
        • 8.4.6.15.1.5 Analyst View
        • 8.4.6.15.1.6 Market Sizing and Forecast
      • 8.4.6.15.2 India
        • 8.4.6.15.2.1 Country Overview
        • 8.4.6.15.2.2 Driving Factors for Market Growth
        • 8.4.6.15.2.3 Factors Challenging the Market
        • 8.4.6.15.2.4 Key Companies Operating in the Country
        • 8.4.6.15.2.5 Analyst View
        • 8.4.6.15.2.6 Market Sizing and Forecast
      • 8.4.6.15.3 Japan
        • 8.4.6.15.3.1 Country Overview
        • 8.4.6.15.3.2 Driving Factors for Market Growth
        • 8.4.6.15.3.3 Factors Challenging the Market
        • 8.4.6.15.3.4 Key Companies Operating in the Country
        • 8.4.6.15.3.5 Analyst View
        • 8.4.6.15.3.6 Market Sizing and Forecast
      • 8.4.6.15.4 South Korea
        • 8.4.6.15.4.1 Country Overview
        • 8.4.6.15.4.2 Driving Factors for Market Growth
        • 8.4.6.15.4.3 Factors Challenging the Market
        • 8.4.6.15.4.4 Key Companies Operating in the Country
        • 8.4.6.15.4.5 Analyst View
        • 8.4.6.15.4.6 Market Sizing and Forecast
      • 8.4.6.15.5 Australia
        • 8.4.6.15.5.1 Country Overview
        • 8.4.6.15.5.2 Driving Factors for Market Growth
        • 8.4.6.15.5.3 Factors Challenging the Market
        • 8.4.6.15.5.4 Key Companies Operating in the Country
        • 8.4.6.15.5.5 Analyst View
        • 8.4.6.15.5.6 Market Sizing and Forecast
      • 8.4.6.15.6 Taiwan
        • 8.4.6.15.6.1 Country Overview
        • 8.4.6.15.6.2 Driving Factors for Market Growth
        • 8.4.6.15.6.3 Factors Challenging the Market
        • 8.4.6.15.6.4 Key Companies Operating in the Country
        • 8.4.6.15.6.5 Analyst View
        • 8.4.6.15.6.6 Market Sizing and Forecast
      • 8.4.6.15.7 Thailand
        • 8.4.6.15.7.1 Country Overview
        • 8.4.6.15.7.2 Driving Factors for Market Growth
        • 8.4.6.15.7.3 Factors Challenging the Market
        • 8.4.6.15.7.4 Key Companies Operating in the Country
        • 8.4.6.15.7.5 Analyst View
        • 8.4.6.15.7.6 Market Sizing and Forecast
      • 8.4.6.15.8 Vietnam
        • 8.4.6.15.8.1 Country Overview
        • 8.4.6.15.8.2 Driving Factors for Market Growth
        • 8.4.6.15.8.3 Factors Challenging the Market
        • 8.4.6.15.8.4 Key Companies Operating in the Country
        • 8.4.6.15.8.5 Analyst View
        • 8.4.6.15.8.6 Market Sizing and Forecast
      • 8.4.6.15.9 Malaysia
        • 8.4.6.15.9.1 Country Overview
        • 8.4.6.15.9.2 Driving Factors for Market Growth
        • 8.4.6.15.9.3 Factors Challenging the Market
        • 8.4.6.15.9.4 Key Companies Operating in the Country
        • 8.4.6.15.9.5 Analyst View
        • 8.4.6.15.9.6 Market Sizing and Forecast
      • 8.4.6.15.10 Rest-of-Asia-Pacific
        • 8.4.6.15.10.1 Country Overview
        • 8.4.6.15.10.2 Driving Factors for Market Growth
        • 8.4.6.15.10.3 Factors Challenging the Market
        • 8.4.6.15.10.4 Key Companies Operating in the Country
        • 8.4.6.15.10.5 Analyst View
        • 8.4.6.15.10.6 Market Sizing and Forecast
• 8.5 Latin America
  • 8.5.1 Regional Overview
  • 8.5.2 Driving Factors for Market Growth
  • 8.5.3 Factors Challenging the Market
  • 8.5.4 Key Companies Operating in the Region
  • 8.5.5 Analyst View
  • 8.5.6 Market Sizing and Forecast
    • 8.5.6.1 Latin America Genetic Screening and Testing for Reproductive Health Market, by Country
    • 8.5.6.2 Latin America Genetic Screening and Testing for Reproductive Health Market, by Testing Volume
    • 8.5.6.3 Latin America Genetic Screening and Testing for Reproductive Health Market, by Testing Volume, by Preimplantation Genetic Testing (PGT)
    • 8.5.6.4 Latin America Genetic Screening and Testing for Reproductive Health Market, Testing Volume, by PGT-A Biopsy Samples Tested
    • 8.5.6.5 Latin America Genetic Screening and Testing for Reproductive Health Market, by Offering
    • 8.5.6.6 Latin America Genetic Screening and Testing for Reproductive Health Market, by Products
    • 8.5.6.7 Latin America Genetic Screening and Testing for Reproductive Health Market, by Test Type
    • 8.5.6.8 Latin America Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Carrier Screening)
    • 8.5.6.9 Latin America Genetic Screening and Testing for Reproductive Health Market, Test Type, (by Preimplantation Genetic Testing (PGT))
    • 8.5.6.10 Latin America Genetic Screening and Testing for Reproductive Health Market, By Technology Approach
    • 8.5.6.11 Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Carrier Screening
    • 8.5.6.12 Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Infertility Genetic Testing
    • 8.5.6.13 Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Preimplantation Genetic Testing (PGT)
    • 8.5.6.14 Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Non-Invasive Prenatal Testing
    • 8.5.6.15 Latin America Genetic Screening and Testing for Reproductive Health Market, Technology Approach, By Others
      • 8.5.6.15.1 Brazil
        • 8.5.6.15.1.1 Country Overview
        • 8.5.6.15.1.2 Driving Factors for Market Growth
        • 8.5.6.15.1.3 Factors Challenging the Market
        • 8.5.6.15.1.4 Key Companies Operating in the Country
        • 8.5.6.15.1.5 Analyst View
        • 8.5.6.15.1.6 Market Sizing and Forecast
      • 8.5.6.15.2 Mexico
        • 8.5.6.15.2.1 Country Overview
        • 8.5.6.15.2.2 Driving Factors for Market Growth
        • 8.5.6.15.2.3 Factors Challenging the Market
        • 8.5.6.15.2.4 Key Companies Operating in the Country
        • 8.5.6.15.2.5 Analyst View
        • 8.5.6.15.2.6 Market Sizing and Forecast
      • 8.5.6.15.3 Argentina
        • 8.5.6.15.3.1 Country Overview
        • 8.5.6.15.3.2 Driving Factors for Market Growth
        • 8.5.6.15.3.3 Factors Challenging the Market
        • 8.5.6.15.3.4 Key Companies Operating in the Country
        • 8.5.6.15.3.5 Analyst View
        • 8.5.6.15.3.6 Market Sizing and Forecast
      • 8.5.6.15.4 Colombia
        • 8.5.6.15.4.1 Country Overview
        • 8.5.6.15.4.2 Driving Factors for Market Growth
        • 8.5.6.15.4.3 Factors Challenging the Market
        • 8.5.6.15.4.4 Key Companies Operating in the Country
        • 8.5.6.15.4.5 Analyst View
        • 8.5.6.15.4.6 Market Sizing and Forecast
      • 8.5.6.15.5 Chile
        • 8.5.6.15.5.1 Country Overview
        • 8.5.6.15.5.2 Driving Factors for Market Growth
        • 8.5.6.15.5.3 Factors Challenging the Market
        • 8.5.6.15.5.4 Key Companies Operating in the Country
        • 8.5.6.15.5.5 Analyst View
        • 8.5.6.15.5.6 Market Sizing and Forecast
      • 8.5.6.15.6 Peru
        • 8.5.6.15.6.1 Country Overview
        • 8.5.6.15.6.2 Driving Factors for Market Growth
        • 8.5.6.15.6.3 Factors Challenging the Market
        • 8.5.6.15.6.4 Key Companies Operating in the Country
        • 8.5.6.15.6.5 Analyst View
        • 8.5.6.15.6.6 Market Sizing and Forecast
      • 8.5.6.15.7 Costa Rica
        • 8.5.6.15.7.1 Country Overview
        • 8.5.6.15.7.2 Driving Factors for Market Growth
        • 8.5.6.15.7.3 Factors Challenging the Market
        • 8.5.6.15.7.4 Key Companies Operating in the Country
        • 8.5.6.15.7.5 Analyst View
        • 8.5.6.15.7.6 Market Sizing and Forecast
      • 8.5.6.15.8 Ecuador
        • 8.5.6.15.8.1 Country Overview
        • 8.5.6.15.8.2 Driving Factors for Market Growth
        • 8.5.6.15.8.3 Factors Challenging the Market
        • 8.5.6.15.8.4 Key Companies Operating in the Country
        • 8.5.6.15.8.5 Analyst View
        • 8.5.6.15.8.6 Market Sizing and Forecast
      • 8.5.6.15.9 Panama
        • 8.5.6.15.9.1 Country Overview
        • 8.5.6.15.9.2 Driving Factors for Market Growth
        • 8.5.6.15.9.3 Factors Challenging the Market
        • 8.5.6.15.9.4 Key Companies Operating in the Country
        • 8.5.6.15.9.5 Analyst View
        • 8.5.6.15.9.6 Market Sizing and Forecast
      • 8.5.6.15.10 Puerto Rico
        • 8.5.6.15.10.1 Country Overview
        • 8.5.6.15.10.2 Driving Factors for Market Growth
        • 8.5.6.15.10.3 Factors Challenging the Market
        • 8.5.6.15.10.4 Key Companies Operating in the Country
        • 8.5.6.15.10.5 Analyst View
        • 8.5.6.15.10.6 Market Sizing and Forecast
      • 8.5.6.15.11 Dominican Republic
        • 8.5.6.15.11.1 Country Overview
        • 8.5.6.15.11.2 Driving Factors for Market Growth
        • 8.5.6.15.11.3 Factors Challenging the Market
        • 8.5.6.15.11.4 Key Companies Operating in the Country
        • 8.5.6.15.11.5 Analyst View
        • 8.5.6.15.11.6 Market Sizing and Forecast
      • 8.5.6.15.12 Rest-of-Latin America
        • 8.5.6.15.12.1 Country Overview
        • 8.5.6.15.12.2 Driving Factors for Market Growth
        • 8.5.6.15.12.3 Factors Challenging the Market
        • 8.5.6.15.12.4 Key Companies Operating in the Country
        • 8.5.6.15.12.5 Analyst View
        • 8.5.6.15.12.6 Market Sizing and Forecast

9 Competitive Benchmarking and Company Profiles

• 9.1 Company Share Analysis
  • 9.1.1 Company Share Analysis (Product)
  • 9.1.2 Company Share Analysis (Services)
• 9.2 Product Benchmarking (by Company)
  • 9.2.1 By Offering
  • 9.2.2 By Offering
• 9.3 Key Strategies and Developments
  • 9.3.1 Impact on the Global Genetic Screening and Testing for Reproductive Health Market
• 9.4 Company Profiles
  • 9.4.1 Company Offering Both Assays and Instruments
    • 9.4.1.1 Thermo Fisher Scientific Inc.
      • 9.4.1.1.1 Overview
      • 9.4.1.1.2 Top Product/Service Portfolio
      • 9.4.1.1.3 Top Competitors
      • 9.4.1.1.4 Key Personnel
      • 9.4.1.1.5 Analyst View
    • 9.4.1.2 Illumina, Inc.
      • 9.4.1.2.1 Overview
      • 9.4.1.2.2 Top Product/Service Portfolio
      • 9.4.1.2.3 Top Competitors
      • 9.4.1.2.4 Key Personnel
      • 9.4.1.2.5 Analyst View
    • 9.4.1.3 Revvity, Inc.
      • 9.4.1.3.1 Overview
      • 9.4.1.3.2 Top Product/Service Portfolio
      • 9.4.1.3.3 Top Competitors
      • 9.4.1.3.4 Key Personnel
      • 9.4.1.3.5 Analyst View
    • 9.4.1.4 GeneMind Biosciences Co., Ltd
      • 9.4.1.4.1 Overview
      • 9.4.1.4.2 Top Product/Service Portfolio
      • 9.4.1.4.3 Top Competitors
      • 9.4.1.4.4 Key Personnel
      • 9.4.1.4.5 Analyst View
    • 9.4.1.5 F. Hoffmann-La Roche Ltd.
      • 9.4.1.5.1 Overview
      • 9.4.1.5.2 Top Product/Service Portfolio
      • 9.4.1.5.3 Top Competitors
      • 9.4.1.5.4 Key Personnel
      • 9.4.1.5.5 Analyst View
  • 9.4.2 Company Offering Assays/ Kits
    • 9.4.2.1 Yikon Genomics
      • 9.4.2.1.1 Overview
      • 9.4.2.1.2 Top Product/Service Portfolio
      • 9.4.2.1.3 Top Competitors
      • 9.4.2.1.4 Key Personnel
      • 9.4.2.1.5 Analyst View
    • 9.4.2.2 Takara Bio Inc.
      • 9.4.2.2.1 Overview
      • 9.4.2.2.2 Top Product/Service Portfolio
      • 9.4.2.2.3 Top Competitors
      • 9.4.2.2.4 Key Personnel
      • 9.4.2.2.5 Analyst View
  • 9.4.3 Platform Providers
    • 9.4.3.1 MGI Tech Co., Ltd.
      • 9.4.3.1.1 Overview
      • 9.4.3.1.2 Top Product/Service Portfolio
      • 9.4.3.1.3 Top Competitors
      • 9.4.3.1.4 Key Personnel
      • 9.4.3.1.5 Analyst View
  • 9.4.4 Service Provider
    • 9.4.4.1 Natera, Inc.
      • 9.4.4.1.1 Overview
      • 9.4.4.1.2 Top Product/Service Portfolio
      • 9.4.4.1.3 Top Competitors
      • 9.4.4.1.4 Key Personnel
      • 9.4.4.1.5 Analyst View
    • 9.4.4.2 Myriad Genetics, Inc.
      • 9.4.4.2.1 Overview
      • 9.4.4.2.2 Top Product/Service Portfolio
      • 9.4.4.2.3 Top Competitors
      • 9.4.4.2.4 Key Personnel
      • 9.4.4.2.5 Analyst View
    • 9.4.4.3 Labcorp
      • 9.4.4.3.1 Overview
      • 9.4.4.3.2 Top Product/Service Portfolio
      • 9.4.4.3.3 Top Competitors
      • 9.4.4.3.4 Key Personnel
      • 9.4.4.3.5 Analyst View
    • 9.4.4.4 Quest Diagnostics Incorporated
      • 9.4.4.4.1 Overview
      • 9.4.4.4.2 Top Product/Service Portfolio
      • 9.4.4.4.3 Top Competitors
      • 9.4.4.4.4 Key Personnel
      • 9.4.4.4.5 Analyst View
    • 9.4.4.5 Vitrolife AB
      • 9.4.4.5.1 Overview
      • 9.4.4.5.2 Top Product/Service Portfolio
      • 9.4.4.5.3 Top Competitors
      • 9.4.4.5.4 Key Personnel
      • 9.4.4.5.5 Analyst View
    • 9.4.4.6 Fulgent Genetics
      • 9.4.4.6.1 Overview
      • 9.4.4.6.2 Top Product/Service Portfolio
      • 9.4.4.6.3 Top Competitors
      • 9.4.4.6.4 Key Personnel
      • 9.4.4.6.5 Analyst View
  • 9.4.5 List of Other Companies

10 Research Methodology

• 10.1 Data Sources
  • 10.1.1 Primary Data Sources
  • 10.1.2 Secondary Data Sources
  • 10.1.3 Data Triangulation
• 10.2 Market Estimation and Forecast